Pfizer Inc. has been on an M&A buying spree over the last year, powered by the unprecedented returns from its COVID-19 vaccine Comirnaty and antiviral Paxlovid and with the aim of finding the next big commercial wins to fuel growth in the second half of the decade. For worldwide president of R&D Mikael Dolsten, that means finding new assets and talent and finding ways to continue successfully building the R&D organization as new groups join the big pharma.
Dolsten sat down with Scrip for an interview at the Galien Foundation Forum in New York on 26 October, and while he reflected on the experience of developing the world-changing COVID-19 products in the first part of the interview, he also discussed how the company is now directing some of the windfall from that success into business development and pipeline investment
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?